Please login to the form below

Not currently logged in
Email:
Password:

GW Pharma

This page shows the latest GW Pharma news and features for those working in and with pharma, biotech and healthcare.

GW Pharma's cannabis-based medicine to be tested in dementia

GW Pharma's cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK. Alzheimer’s Research UK is to sponsor a clinical trial of GW Pharmaceuticals’ Sativex to treat agitation and aggression in people with

Latest news

  • Medicinal cannabis firm Althea enters UK market Medicinal cannabis firm Althea enters UK market

    For now, it says the default choice for treatment is GW Pharma’s Epidiolex, which is approved in the US but not in Europe, and is says it does not recommend

  • UK biotech booms in 2018, despite Brexit worries UK biotech booms in 2018, despite Brexit worries

    There were just five initial public offering (IPOs) in the year, raising £432m, with another £658m coming from follow-on public financings, including a £273m round from GW Pharma. ... 2018’s UK IPOs came fromSensyne Health, Acacia Pharma and

  • Blackwood returns as new life sciences minister Blackwood returns as new life sciences minister

    companies including GW Pharma. ... Roche, Celgene, IQVIA and Oxford Biomedica. Her role also includes looking at ways in which the sector can make the most of Brexit - although the UK's pharma and biotech sector

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    drugs, driven on by new pharma and biotech science, and the FDA's determination to accelerate its review times. ... in the body where the tumour originated (after Merck &Co’s Keytruda), and GW Pharma’s epilepsy therapy Epidiolex (cannabidiol) which

  • UK life sciences gets some Brexit relief with £1.3bn sector deal UK life sciences gets some Brexit relief with £1.3bn sector deal

    Another £200m is coming from other pharma companies. That includes £46m package from IQVIA that will go towards the creation of the organisation’s fourth ‘Prime Site’ for clinical research – a ... CRUK is also pitching in with a £14m

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    A handful of legitimate companies is now pioneering these products, led by GW Pharma, the UK-headquartered firm that has been working in the area since the late 1990s. ... GW Pharma gained an historic approval for its drug Epidiolex from the FDA in June

  • Pharma deals during January 2014 Pharma deals during January 2014

    Another option, open to some European companies, is to raise cash in the US, for example, in early January GW Pharma raised $87.9m on NASDAQ. . ... See a table listing all the major pharma mergers, acquisitions and collaborations agreed during January

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    I look forward to contributing to GW’s drug discovery efforts and to advancing the next generation of pipeline candidates.”. ... Justin Gover, GW’s chief executive officer, said: “I am delighted to welcome Volker and Ben to GW in these important R

  • GW Pharmaceuticals promotes Adam George to MD GW Pharmaceuticals promotes Adam George to MD

    Gover said: “These important leadership appointments reflect GW’s continuing evolution into a transatlantic commercial-stage biopharmaceutical company. ... In his new role he will be tasked with ensuring GW’s UK operations achieve their strategic

  • GW Pharma appoints Julian Gangolli as North American president GW Pharma appoints Julian Gangolli as North American president

    Appointment coincides with GW Pharma’s US launch. Biopharma company GW Pharma has named Julian Gangolli as its president for North America. ... GW Pharma is also relocating its CEO, Justin Glover, to the US to support its imminent launch in the States.

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    Appointed VP clinical research at company specialising in cannabinoids. Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma. ... This is an exciting time to be joining GW, with a number of important products currently under

More from appointments
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics